ARYx Therapeutics, Inc.
ARYX
$0.00
$0.000.00%
OTC PK
| 09/30/2010 | 06/30/2010 | 03/31/2010 | 12/31/2009 | 09/30/2009 | |
|---|---|---|---|---|---|
| Net Income | 69.14% | 61.29% | 35.05% | 55.65% | -352.32% |
| Total Depreciation and Amortization | 12.57% | -32.65% | -14.33% | -5.43% | -33.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -66.18% | -69.37% | -13.30% | -54.35% | -0.48% |
| Change in Net Operating Assets | -448.75% | 84.22% | 70.78% | -158.21% | 103.39% |
| Cash from Operations | 40.42% | 66.22% | 45.03% | 42.83% | 44.90% |
| Capital Expenditure | 0.00% | -- | -- | -46.67% | 86.21% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -90.90% | 215.25% | 122.22% | 62.06% | 607.06% |
| Cash from Investing | -91.14% | 207.94% | 121.24% | 62.17% | 561.77% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 30.53% | -10,080.00% | -1,732.10% | -3,565.00% | -90.76% |
| Issuance of Common Stock | -54.17% | -- | 18,797.06% | -94.76% | 269.23% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 486.56% | -1,765.26% | 3,654.68% | -102.88% | -87.60% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 130.46% | 53.40% | 91.80% | -96.29% | 62.93% |